ES2175161T3 - Derivados de piperazina como antagonistas de taquiquinina. - Google Patents

Derivados de piperazina como antagonistas de taquiquinina.

Info

Publication number
ES2175161T3
ES2175161T3 ES96941859T ES96941859T ES2175161T3 ES 2175161 T3 ES2175161 T3 ES 2175161T3 ES 96941859 T ES96941859 T ES 96941859T ES 96941859 T ES96941859 T ES 96941859T ES 2175161 T3 ES2175161 T3 ES 2175161T3
Authority
ES
Spain
Prior art keywords
piperazine derivatives
taquiquinine
antagonists
treatment
taquiquinina
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96941859T
Other languages
English (en)
Inventor
Masaaki Matsuo
Takashi Manabe
Nobukiyo Konishi
Kazuhiko Take
Norihiro Igari
Shinji Shigenaga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9525841.4A external-priority patent/GB9525841D0/en
Priority claimed from AUPN9891A external-priority patent/AUPN989196A0/en
Priority claimed from AUPO2683A external-priority patent/AUPO268396A0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2175161T3 publication Critical patent/ES2175161T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

LA INVENCION SE REFIERE A DERIVADOS DE PIPERAZINA DE FORMULA (I), DONDE CADA SIMBOLO ES TAL Y COMO SE DEFINE EN LA DESCRIPCION, ASI COMO A SUS SALES FARMACEUTICAMENTE ACEPTABLES, A PROCEDIMIENTOS DE PREPARACION DE LOS MISMOS Y A SU UTILIZACION PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TAQUIQUININA EN SERES HUMANOS O ANIMALES.
ES96941859T 1995-12-18 1996-12-12 Derivados de piperazina como antagonistas de taquiquinina. Expired - Lifetime ES2175161T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9525841.4A GB9525841D0 (en) 1995-12-18 1995-12-18 Piperazine derivatives
AUPN9891A AUPN989196A0 (en) 1996-05-16 1996-05-16 Piperazine derivatives
AUPO2683A AUPO268396A0 (en) 1996-09-30 1996-09-30 Piperazine derivatives

Publications (1)

Publication Number Publication Date
ES2175161T3 true ES2175161T3 (es) 2002-11-16

Family

ID=27157927

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96941859T Expired - Lifetime ES2175161T3 (es) 1995-12-18 1996-12-12 Derivados de piperazina como antagonistas de taquiquinina.

Country Status (13)

Country Link
US (2) US6087357A (es)
EP (1) EP0873320B1 (es)
JP (1) JP2000502100A (es)
KR (1) KR20000064415A (es)
CN (1) CN1209125A (es)
AT (1) ATE219064T1 (es)
AU (1) AU714931B2 (es)
CA (1) CA2240835A1 (es)
DE (1) DE69621831T2 (es)
ES (1) ES2175161T3 (es)
HU (1) HUP9901037A3 (es)
IL (1) IL124674A0 (es)
WO (1) WO1997022597A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968929A (en) * 1996-10-30 1999-10-19 Schering Corporation Piperazino derivatives as neurokinin antagonists
ES2263173T3 (es) * 1996-10-30 2006-12-01 Schering Corporation Derivados piperazino como antagonistas de neurokinina.
US5783579A (en) * 1996-12-20 1998-07-21 Schering Corporation Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists
AU743723B2 (en) * 1997-06-17 2002-01-31 Astellas Pharma Inc. Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists
AUPO735997A0 (en) 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
BR9917047A (pt) * 1998-12-14 2002-07-30 Fujisawa Pharmaceutical Co Composto de piperazina, método para prepará-lo, composição farmacêutica contendo-o e seu uso
US6331541B1 (en) 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6525069B1 (en) 1998-12-18 2003-02-25 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2347770A1 (en) 1998-12-18 2000-06-22 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU3126600A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000035454A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6441001B1 (en) 1998-12-18 2002-08-27 Bristol-Myers Squibb Pharma Company 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
AU2056800A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company Heterocyclic piperidines as modulators of chemokine receptor activity
US6897234B2 (en) 1999-12-17 2005-05-24 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
TW591025B (en) * 2000-06-13 2004-06-11 Fujisawa Pharmaceutical Co Production of the piperazine derivative
MXPA02012712A (es) 2000-06-30 2003-04-25 Bristol Myers Squibb Pharma Co N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
DE10036818A1 (de) * 2000-07-28 2002-02-07 Solvay Pharm Gmbh Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten
UA75425C2 (en) * 2001-07-09 2006-04-17 Piperazine oxime derivatives with antagonistic activity to nk-1 receptor, use thereof, a pharmaceutical composition based thereon, a method for producing and a method for producing intermediary compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
JP2005504043A (ja) * 2001-08-10 2005-02-10 パラチン テクノロジーズ インク． 生物学的に活性な金属ペプチド類のペプチド模倣体類
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
UA77515C2 (en) * 2002-04-04 2006-12-15 Diazabicyclo alkane derivatives possessing neuroldnin-nk1 receptor antagonistic activity
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
AU2005311930B9 (en) 2004-12-03 2009-09-10 Merck Sharp & Dohme Corp. Substituted piperazines as CB1 antagonists
EP1909797A4 (en) * 2005-08-02 2013-02-27 Neurogen Corp DIPIPERAZINYL KETONE AND RELATED ANALOG
PE20071320A1 (es) 2006-01-18 2007-12-29 Schering Corp Moduladores de receptores cannabinoides
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
KR20090112722A (ko) 2007-01-24 2009-10-28 글락소 그룹 리미티드 3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진 또는 ｒ(-)-2,4-디아미노-5-(2,3-디클로로페닐)-6-플루오로메틸 피리미딘 및 ｎｋ1을 포함하는 제약 조성물
NZ582249A (en) 2007-06-28 2012-06-29 Intervet Int Bv Substituted piperazines as cb1 antagonists
EP2558087A4 (en) 2010-03-11 2013-09-11 Univ New York AMID COMPOUNDS AS RORYT MODULATORS AND ITS USES
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
AU2015267909B2 (en) * 2014-05-28 2018-03-22 Glaxosmithkline Intellectual Property Development Limited Novel compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3935214A (en) * 1968-07-26 1976-01-27 Donau-Pharmazie Gesellschaft M.B.H. 2-or 3 keto-3-or-2-phenyl-1,4-disubstituted piperazines
US5164388A (en) * 1988-10-19 1992-11-17 Abbott Laboratories Heterocyclic peptide renin inhibitors
US5238938A (en) * 1989-02-10 1993-08-24 Otsuka Pharmaceutical Co., Ltd. Indole derivatives
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
GB9222486D0 (en) * 1992-10-26 1992-12-09 Merck Sharp & Dohme Therapeutic agents
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
IL111730A (en) * 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them
US5883098A (en) * 1993-11-29 1999-03-16 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
DK0815105T3 (da) * 1995-03-15 2002-01-21 Aventis Pharma Inc Heterocyklisk substituerede piperazinonderivater som tachykininreceptor-antagonister
ES2224164T3 (es) * 1995-04-13 2005-03-01 Aventis Pharmaceuticals Inc. Nuevos derivados de piperazina sustituida que tienen actividad como antagonistas de los receptores de taququinina.
WO1996037489A1 (en) * 1995-05-25 1996-11-28 Fujisawa Pharmaceutical Co., Ltd. 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists

Also Published As

Publication number Publication date
EP0873320A1 (en) 1998-10-28
EP0873320B1 (en) 2002-06-12
WO1997022597A1 (en) 1997-06-26
HUP9901037A2 (hu) 1999-07-28
CA2240835A1 (en) 1997-06-26
HUP9901037A3 (en) 2001-11-28
JP2000502100A (ja) 2000-02-22
DE69621831D1 (de) 2002-07-18
ATE219064T1 (de) 2002-06-15
AU1110697A (en) 1997-07-14
US6087357A (en) 2000-07-11
US20020010182A1 (en) 2002-01-24
CN1209125A (zh) 1999-02-24
AU714931B2 (en) 2000-01-13
KR20000064415A (ko) 2000-11-06
DE69621831T2 (de) 2003-01-02
IL124674A0 (en) 1998-12-06

Similar Documents

Publication Publication Date Title
ES2175161T3 (es) Derivados de piperazina como antagonistas de taquiquinina.
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
ES2161290T3 (es) Derivados de quinazolina.
ES2054860T5 (es) Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.
AR034897A1 (es) Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
ES2120993T3 (es) Agentes antitromboticos.
UY27892A1 (es) Benzoilureas heterociclicamente sustituidas, procedimiento para su preparacion y su uso como farmacos.
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP055747A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
ES2196377T3 (es) Derivados de naftiridina.
ES2075648T3 (es) Composicion para frenar la caida de los cabellos, y para inducir y estimular su crecimiento, a base de derivados de pirimidinas-n-oxido trisustituidas en las posiciones 2, 4 y 6 por una funcion amina, y nuevos compuestos de pirimidina-n-oxido.
MX9300786A (es) Compuestos hipolipidaemicos.
AR013001A1 (es) Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina.
ES2184131T3 (es) Derivados de benzamidina y su utilizacion como medicamentos con efecto antagonista de ltb4.
ES2181130T3 (es) Antagonistas quinazolin-4-ona del ampa.
AR050260A1 (es) Derivados de diarilmetilpiperazinas, su preparacion y su utilizacion
ES2043665T3 (es) 6,11-dihidro-11-(4-piperidiliden)-5h-benzo-(5,6)-ciclohepta-(1,2-b)-piridinas y composiciones y metodos de uso.
ES2164465T3 (es) Uso de aminometil-cromanos sustituidos para evitar la degeneracion neuronal y para estimular la regeneracion neuronal.
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
AR030537A1 (es) Acidos quinolincarboxilicos y naftiridincarboxilico antibacterianos
ES2095208T3 (es) Compuestos de tienotriazolodiazepina y usos farmaceuticos de los mismos.
MX9301404A (es) Derivados de 2-oxoquinolina, procedimiento para su preparacion, preparado farmaceutico que los contiene y procedimiento para la obtencion de tal preparado farmaceutico.
AR025351A1 (es) Agonistas retinoides selectivos par
ES2179857T3 (es) Derivados de quinoleina sustituidos, procedimiento para su preparacion y su utilizacion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 873320

Country of ref document: ES